CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
12.05
3.72%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026346 %
Charges from full value of position ($-5.01)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026346%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004124 %
Charges from full value of position ($0.78)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

AVITA Medical Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 11.55
Open* 11.33
1-Year Change* 65.4%
Day's Range* 11.33 - 12.11
52 wk Range 6.29-21.70
Average Volume (10 days) 278.27K
Average Volume (3 months) 3.76M
Market Cap 259.85M
P/E Ratio -100.00K
Shares Outstanding 25.55M
Revenue 45.40M
EPS -1.33
Dividend (Yield %) N/A
Beta 1.52
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 4, 2023 11.55 0.44 3.96% 11.11 11.64 10.85
Dec 1, 2023 11.21 0.72 6.86% 10.49 11.26 10.48
Nov 30, 2023 10.61 0.07 0.66% 10.54 10.73 10.48
Nov 29, 2023 10.62 -0.13 -1.21% 10.75 10.92 10.56
Nov 28, 2023 10.75 -0.06 -0.56% 10.81 10.97 10.69
Nov 27, 2023 10.82 0.31 2.95% 10.51 10.95 10.38
Nov 24, 2023 10.58 0.21 2.03% 10.37 10.88 10.28
Nov 22, 2023 10.46 0.28 2.75% 10.18 10.81 10.15
Nov 21, 2023 10.13 -0.69 -6.38% 10.82 11.02 9.99
Nov 20, 2023 12.48 0.16 1.30% 12.32 12.68 12.12
Nov 17, 2023 12.57 0.10 0.80% 12.47 12.63 12.19
Nov 16, 2023 12.56 -0.11 -0.87% 12.67 12.77 12.03
Nov 15, 2023 12.89 -0.41 -3.08% 13.30 13.64 12.86
Nov 14, 2023 13.39 0.70 5.52% 12.69 13.47 12.53
Nov 13, 2023 12.49 1.47 13.34% 11.02 12.64 10.98
Nov 10, 2023 11.26 -0.93 -7.63% 12.19 12.38 10.75
Nov 9, 2023 9.86 -0.38 -3.71% 10.24 10.24 9.78
Nov 8, 2023 10.31 -0.08 -0.77% 10.39 10.49 10.14
Nov 7, 2023 10.52 0.11 1.06% 10.41 10.68 10.25
Nov 6, 2023 10.41 -0.24 -2.25% 10.65 10.65 10.30

AVITA Medical, Inc. Events

Time (UTC) Country Event
Tuesday, December 5, 2023

Time (UTC)

22:00

Country

US

Event

AVITA Medical Inc Investor Webinar
AVITA Medical Inc Investor Webinar

Forecast

-

Previous

-
Wednesday, February 21, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 AVITA Medical Inc Earnings Release
Q4 2023 AVITA Medical Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2021 2020
Total revenue 34.421 13.956 29.232 14.263
Revenue 34.421 13.956 29.232 14.263
Cost of Revenue, Total 5.666 1.861 5.723 2.667
Gross Profit 28.755 12.095 23.509 11.596
Total Operating Expense 61.926 28.379 55.772 56.942
Selling/General/Admin. Expenses, Total 45.243 19.426 37.06 49.434
Research & Development 13.857 7.586 14.818 8.461
Unusual Expense (Income) 0.375 0.086 0.226 0.306
Other Operating Expenses, Total -3.215 -0.58 -2.055 -3.926
Operating Income -27.505 -14.423 -26.54 -42.679
Interest Income (Expense), Net Non-Operating -0.016 -0.017 -0.022 -0.033
Other, Net 0.892 0.038 0.017 0.686
Net Income Before Taxes -26.629 -14.402 -26.545 -42.026
Net Income After Taxes -26.665 -14.427 -26.583 -42.03
Net Income Before Extra. Items -26.665 -14.427 -26.583 -42.03
Net Income -26.665 -14.427 -26.583 -42.03
Income Available to Common Excl. Extra. Items -26.665 -14.427 -26.583 -42.03
Income Available to Common Incl. Extra. Items -26.665 -14.427 -26.583 -42.03
Diluted Net Income -26.665 -14.427 -26.583 -42.03
Diluted Weighted Average Shares 25.0002 24.9154 22.6743 20.291
Diluted EPS Excluding Extraordinary Items -1.06659 -0.57904 -1.17238 -2.07137
Diluted Normalized EPS -1.05684 -0.5768 -1.16591 -2.06156
Dividends per Share - Common Stock Primary Issue 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 11.753 10.55 9.455 9.092 8.335
Revenue 11.753 10.55 9.455 9.092 8.335
Cost of Revenue, Total 2.202 1.6 1.256 1.405 1.325
Gross Profit 9.551 8.95 8.199 7.687 7.01
Total Operating Expense 22.918 20.461 15.363 14.84 14.697
Selling/General/Admin. Expenses, Total 16.162 14.815 11.663 10.333 10.763
Research & Development 5.076 4.586 3.379 3.799 3.059
Unusual Expense (Income) 0.002 0.067 0.091 0.125 0.061
Other Operating Expenses, Total -0.53 -0.627 -1.026 -0.904 -0.551
Operating Income -11.165 -9.911 -5.908 -5.748 -6.362
Interest Income (Expense), Net Non-Operating -0.007 -0.004 -0.006 -0.006 -0.004
Other, Net 0.801 0.725 0.585 0.17 0.109
Net Income Before Taxes -10.371 -9.19 -5.329 -5.584 -6.257
Net Income After Taxes -10.384 -9.22 -5.353 -5.588 -6.261
Net Income Before Extra. Items -10.384 -9.22 -5.353 -5.588 -6.261
Net Income -10.384 -9.22 -5.353 -5.588 -6.261
Income Available to Common Excl. Extra. Items -10.384 -9.22 -5.353 -5.588 -6.261
Income Available to Common Incl. Extra. Items -10.384 -9.22 -5.353 -5.588 -6.261
Diluted Net Income -10.384 -9.22 -5.353 -5.588 -6.261
Diluted Weighted Average Shares 25.2397 25.2021 25.0837 25.007 24.9712
Diluted EPS Excluding Extraordinary Items -0.41141 -0.36584 -0.21341 -0.22346 -0.25073
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.41136 -0.36411 -0.21105 -0.22021 -0.24914
Interest Expense (Income) - Net Operating 0.006 0.02 0.082 0.04
  • Annual
  • Quarterly
2022 2021 2021 2020
Total Current Assets 87.458 92.132 121.33 78.387
Cash and Short Term Investments 79.342 85.16 110.746 73.639
Cash 73.639
Total Receivables, Net 4.96 3.513 7.883 2.507
Accounts Receivable - Trade, Net 3.935 3.19 3.467 2.076
Total Inventory 2.125 2.132 1.647 1.125
Prepaid Expenses 0.921 1.124 0.853 0.792
Other Current Assets, Total 0.11 0.203 0.201 0.324
Total Assets 98.264 116.015 125.501 82.462
Property/Plant/Equipment, Total - Net 2.051 2.806 2.938 3.71
Property/Plant/Equipment, Total - Gross 4.203 4.501 4.359 4.591
Accumulated Depreciation, Total -2.152 -1.695 -1.421 -0.881
Intangibles, Net 0.465 0.443 0.472 0.364
Other Long Term Assets, Total 1.36 0.942 0.761 0.001
Total Current Liabilities 10.693 9.146 7.39 7.709
Payable/Accrued 3.002 2.708 3.12 4.333
Accrued Expenses 7.235 6.083 4.023 3.349
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.011
Other Current Liabilities, Total 0.456 0.355 0.247 0.016
Total Liabilities 13.524 11.391 9.846 10.061
Total Long Term Debt 0 0 0 0
Other Liabilities, Total 2.831 2.245 2.456 2.352
Total Equity 84.74 104.624 115.655 72.401
Common Stock 0.003 0.003 0.003 0.003
Additional Paid-In Capital 339.825 332.484 328.889 259.165
Retained Earnings (Accumulated Deficit) -262.588 -235.923 -221.496 -194.913
Other Equity, Total 7.5 8.06 8.259 8.146
Total Liabilities & Shareholders’ Equity 98.264 116.015 125.501 82.462
Total Common Shares Outstanding 25.2084 24.9257 24.8959 21.4679
Cash & Equivalents 18.164 55.511 110.746
Short Term Investments 61.178 29.649
Long Term Investments 6.93 19.692
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 73.927 77.495 82.761 87.458 91.72
Cash and Short Term Investments 60.118 66.047 73.451 79.342 84.172
Cash
Total Receivables, Net 7.886 7.015 5.37 4.96 4.508
Accounts Receivable - Trade, Net 6.159 6.048 4.825 3.935 3.699
Total Inventory 4.377 3.058 2.811 2.125 1.96
Prepaid Expenses 1.509 1.375 1.116 0.921 0.862
Other Current Assets, Total 0.037 0 0.013 0.11 0.218
Total Assets 81.014 86.33 92.622 98.264 99.932
Property/Plant/Equipment, Total - Net 4.469 3.249 3.148 2.051 2.255
Property/Plant/Equipment, Total - Gross 6.726 5.64 5.426 4.203 4.284
Accumulated Depreciation, Total -2.257 -2.391 -2.278 -2.152 -2.029
Intangibles, Net 0.459 0.456 0.461 0.465 0.449
Other Long Term Assets, Total 2.159 2.376 2.063 1.36 1.496
Total Current Liabilities 11.836 13.81 11.486 10.693 9.513
Payable/Accrued 3.019 3.837 3.752 3.002 3.118
Accrued Expenses 8.047 6.856 4.303 7.235 5.478
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 0.77 3.117 3.431 0.456 0.917
Total Liabilities 18.036 17.683 15.061 13.524 11.946
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 6.2 3.873 3.575 2.831 2.433
Total Equity 62.978 68.647 77.561 84.74 87.986
Common Stock 0.003 0.003 0.003 0.003 0.003
Additional Paid-In Capital 347.192 343.769 342.4 339.825 337.995
Retained Earnings (Accumulated Deficit) -290.904 -282.192 -271.808 -262.588 -257.235
Other Equity, Total 6.687 7.067 6.966 7.5 7.223
Total Liabilities & Shareholders’ Equity 81.014 86.33 92.622 98.264 99.932
Total Common Shares Outstanding 25.5507 25.4476 25.3278 25.2084 25.0309
Cash & Equivalents 50.854 37.485 28.05 18.164 23.613
Short Term Investments 9.264 28.562 45.401 61.178 60.559
Long Term Investments 0 2.754 4.189 6.93 4.012
  • Annual
  • Quarterly
2022 2021 2021 2020
Net income/Starting Line -26.665 -14.427 -26.583 -42.03
Cash From Operating Activities -19.09 -5.501 -25.901 -22.747
Cash From Operating Activities 0.568 0.33 0.715 0.465
Non-Cash Items 8.203 3.921 7.323 17.488
Cash Interest Paid 0.015 0.017 0.003 0.042
Changes in Working Capital -1.196 4.675 -7.356 1.33
Cash From Investing Activities -19.332 -49.682 -1.174 -0.847
Capital Expenditures -0.452 -0.132 -1.174 -0.847
Cash From Financing Activities 0.9 0.007 64.049 77.057
Financing Cash Flow Items 0 -5.109 -5.077
Issuance (Retirement) of Stock, Net 0.9 0.007 69.169 82.176
Issuance (Retirement) of Debt, Net 0 0 -0.011 -0.042
Foreign Exchange Effects -0.026 -0.059 0.133 0.003
Net Change in Cash -37.548 -55.235 37.107 53.466
Cash Taxes Paid 0.017 0.008 0.042
Other Investing Cash Flow Items, Total -18.88 -49.55
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.22 -26.665 -21.312 -15.724 -9.463
Cash From Operating Activities -9.073 -19.09 -15.654 -12.877 -9.37
Cash From Operating Activities 0.135 0.568 0.438 0.3 0.163
Non-Cash Items 3.347 8.203 6.697 5.004 3.383
Cash Taxes Paid 0.009 0.017 0.017 0.017
Cash Interest Paid 0.004 0.015 0.01 0.004 0
Changes in Working Capital -3.335 -1.196 -1.477 -2.457 -3.453
Cash From Investing Activities 18.787 -19.332 -16.174 -7.845 -22.601
Capital Expenditures -0.284 -0.452 -0.382 -0.278 -0.064
Cash From Financing Activities 0.171 0.9 0.001 0.001 0.001
Financing Cash Flow Items 0 0
Issuance (Retirement) of Stock, Net 0.171 0.9 0.001 0.001 0.001
Issuance (Retirement) of Debt, Net 0 0
Foreign Exchange Effects 0.001 -0.026 -0.07 -0.052 -0.006
Net Change in Cash 9.886 -37.548 -31.897 -20.773 -31.976
Other Investing Cash Flow Items, Total 19.071 -18.88 -15.792 -7.567 -22.537
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.0776 1548461 1077008 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.2972 1349634 143802 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8649 475157 225098 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.775 452229 364384 2023-06-30 LOW
Pura Vida Investments, LLC Hedge Fund 1.6733 426321 -372601 2023-06-30 HIGH
Millennium Management LLC Hedge Fund 1.0758 274097 -61379 2023-06-30 HIGH
Two Sigma Investments, LP Hedge Fund 1.0167 259040 81079 2023-06-30 HIGH
Perry (Michael S) Individual Investor 1.0057 256232 26689 2023-01-31 LOW
Calamos Advisors LLC Investment Advisor/Hedge Fund 0.8274 210796 125010 2023-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.7656 195056 151125 2023-06-30 LOW
EAM Investors, LLC Investment Advisor/Hedge Fund 0.682 173756 -81268 2023-06-30 HIGH
Invesco Capital Management LLC Investment Advisor 0.6461 164628 13134 2023-06-30 LOW
Driehaus Capital Management, LLC Investment Advisor/Hedge Fund 0.6393 162877 0 2023-09-30 MED
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.5948 151540 30546 2023-06-30 LOW
Russell Investments Trust Company Investment Advisor 0.5454 138969 138969 2023-06-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 0.4494 114502 -17107 2023-06-30 LOW
GlobeFlex Capital, L.P. Investment Advisor 0.4483 114217 -4645 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.3925 100000 -112336 2023-06-30 HIGH
Assenagon Asset Management S.A. Investment Advisor 0.3571 90984 30137 2023-06-30 HIGH
Nuveen LLC Pension Fund 0.3336 84998 84998 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AVITA Medical, Inc. Company profile

About AVITA Medical Inc

AVITA Medical, Inc. is a regenerative medicine company. The Company is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. It provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AVITA Medical Inc revenues totaled $14M. Net loss totaled to $14.4M. Results are not comparable due to year end change.

Industry: Biotechnology & Medical Research (NEC)

28159 Avenue Stanford
Suite 220
VALENCIA
CALIFORNIA 91355
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

US100

15,864.90 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,019.47 Price
-0.500% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

43,654.85 Price
+3.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading